| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
BML-111 lowers the levels of hypoxia-inducible factor-1α and prevents the synthesis of vascular endothelial growth factor in H22 cells [1]. With an IC50 of 5 nM, BML-111 blocks leukotriene B4-induced cell migration[3].
|
|---|---|
| ln Vivo |
Male imprinted control mice treated with BML-111 (1 mg/kg; i.p.; 15 days) showed reduced tumor-associated angiogenesis and tumor growth in vivo. Additionally, BML-111 can promote in situ cell death while preventing tumor tissue macrophage invasion [1]. LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury are prevented by BML-111. While ACE activity is inhibited by BML-111, ACE2 activity is increased. ACE, AngII, and AngII type 1 receptor (AT1R) expression levels are all decreased by BML-111, although ACE2, angiotensin-(1-7) (Ang-1-7), and Mas are all increased [2].
|
| Animal Protocol |
Animal/Disease Models: Male imprinted control area mice (5-6 weeks old, 18-22 g) were injected with H22 cells [1]
Doses: 1 mg/kg Route of Administration: intraperitoneal (ip) injection; intraperitoneal (ip) injection. H22 cells were injected 5 minutes before and 4 hrs (hrs (hours)) after inoculation, then every 12 hrs (hrs (hours)) for 2 days, then one time/day for the next 3 days, and every other day for the last 10 days. Experimental Results: Inhibition of tumors in vivo Related angiogenesis and tumor growth. |
| References |
|
| Molecular Formula |
C8H16O5
|
|---|---|
| Molecular Weight |
192.211
|
| Exact Mass |
192.099
|
| CAS # |
78606-80-1
|
| PubChem CID |
10899465
|
| Appearance |
Colorless to light yellow solid-liquid Mixture
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
360.8±42.0 °C at 760 mmHg
|
| Flash Point |
143.5±21.4 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.489
|
| LogP |
-1.72
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
13
|
| Complexity |
148
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
OC(C(O)CO)CCCC(OC)=O
|
| InChi Key |
RNMFWAFZUNVQOR-NKWVEPMBSA-N
|
| InChi Code |
InChI=1S/C8H16O5/c1-13-8(12)4-2-3-6(10)7(11)5-9/h6-7,9-11H,2-5H2,1H3/t6-,7+/m0/s1
|
| Chemical Name |
methyl (5S,6R)-5,6,7-trihydroxyheptanoate
|
| Synonyms |
BML-111 BML111 BML 111
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~520.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2026 mL | 26.0132 mL | 52.0264 mL | |
| 5 mM | 1.0405 mL | 5.2026 mL | 10.4053 mL | |
| 10 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
